The Experts below are selected from a list of 771 Experts worldwide ranked by ideXlab platform
Kwang Hyun Kim - One of the best experts on this subject based on the ideXlab platform.
-
ok 432 sclerotherapy in head and neck lymphangiomas long term follow up result
Otolaryngology-Head and Neck Surgery, 2009Co-Authors: Jae Chul Yoo, Myung-whun Sung, Youngjin Ahn, Yune Syung Lim, Hun J Hah, Tackkyun Kwon, Kwang Hyun KimAbstract:Introduction Nonsurgical treatments, such as sclerotherapy have been attempted for head and neck lymphagiomas. Of the available sclerosing agents, Picibanil has shown satisfactory short-term treatment results in many studies, but no study has presented long-term treatment results. Accordingly, in the present study, the authors retrospectively reviewed the long-term treatment results of Picibanil sclerotherapy. Materials and Methods Fifty-five lymphangioma patients who underwent Picibanil sclerotherapy were enrolled. Data about initial and long-term response, recurrence, and excision rate were collected. Results Initial response rates were 83.5 percent and long-term response rates were 76.3 percent. Conclusion Initial and the long-term response rate were equally good for lymphangioma.
-
Picibanil sclerotherapy for intractable chylous leakage after neck dissection
Korean Journal of Otorhinolaryngology-head and Neck Surgery, 2008Co-Authors: Hyun Chang, Youngjin Ahn, Myung-whun Sung, Kwang Hyun KimAbstract:Injury of the thoracic duct after radical neck dissection is a well known complication that occurs in about 2% of patients who undergo radical neck dissection. Subsequent chyle leakage can cause complications such as skin flap necrosis, orocutaneous fistula, electrolyte imbalance and protein loss. Chyle leakage is managed conservatively with total parenteral nutrition and mediumchain triglyceride diet or is treated surgically with leakage site ligation or thoracic duct ligation. Sclerotherapy can be one of the treatment options and tetracycline and povidone-iodine have been reported to be used as sclerosing agents. However, Picibanil sclerotheray for post-neck dissection chyle leakage has not been reported. This paper presents our experience in the management of a intractable chyle leakage which was irresponsive to conservative management and thoracic duct ligation, by successfully employing Picibanil. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:846-9)
-
sclerotherapy with Picibanil ok 432 for congenital lymphatic malformation in the head and neck
Laryngoscope, 2001Co-Authors: Kwang Hyun Kim, Myung-whun Sung, Dongwook Lee, Dongyoung Kim, Sangjun Lee, Chan Ho Hwang, Seokwoo ParkAbstract:Hypothesis/Objectives: Congenital lymphatic malformations of the head and neck (LMHN) present special challenges to the otolaryngologist-head and neck surgeon. Recently, a number of sclerotherapy trials have shown promising results. In this study, we present our experiences with Picibanil (OK-432) sclerotherapy for this lesion. Study Design: Retrospectively review. Methods: We retrospectively reviewed 21 patients who have undergone sclerotherapy with Picibanil for LMHN. Results: Satisfactory response with complete or nearly complete shrinkage of the lesions was observed in 15 cases after repeated sclerotherapy (average, two times). We did not observe any significant morbidity or complications in the patients treated with Picibanil. Reduction in size of the mass was achieved in weeks to months. Some of the patients who had not had any other previous treatment showed remarkable reductions in size even after the first therapy. When we used Picibanil sclerotherapy as a primary treatment for the LMHN, most of our patients showed satisfactory results regardless of the size or location of the lesions. Conclusion: Given with our experience and the reports that failure of Picibanil sclerotherapy does not hinder subsequent surgical salvage procedures, we recommend trying Picibanil sclerotherapy as a primary treatment for the LMHN and performing surgical excision as a secondary modality if the response to the sclerotherapy is not satisfactory.
K. Neumann - One of the best experts on this subject based on the ideXlab platform.
-
Sclerotherapy of cervical cysts with Picibanil (OK-432).
European Archives of Oto-Rhino-Laryngology, 2006Co-Authors: Stephan Knipping, K. Neumann, Gerrit Goetze, Marc BlochingAbstract:The effectiveness of intralesional sclerotherapy of lymphangiomas and ranulas with OK-432 (Picibanil) has been proved in several clinical studies. The aim of our study was to review the effectiveness of sclerotherapy of benign cervical cysts with Picibanil as an alternative method to surgical excision. Between March 2002 and March 2006, a prospective observational study was carried out to assess the effects of Picibanil on cervical cysts. Between 2002 and 2006 we treated 14 patients having cervical cysts through intralesional application of Picibanil with a dose of 0.01 mg/ml. So far we used Picibanil with 13 patients achieving a high success rate. In eight cases we observed, both clinically and ultrasonographically, a nearly complete regression, and a complete regression of the cysts in three cases. In two cases the cysts atrophied. In these cases only residual findings could be observed. In one case we extirpated the remaining cyst. If there is no clear reaction of the cyst to the treatment, an excision is indicated 6 weeks after the injections to gain meaningful histological examination. No significant complication after sclerotherapy with Picibanil was observed. According to our results the application of OK-432 (Picibanil) is a safe and effective primary method for sclerotherapy of benign cervical cysts which can replace surgical extirpation in special cases. However, the risk of malign diseases has to be excluded before the commencement of the Picibanil treatment.
-
Sklerotherapie zystischer Raumforderungen im Halsbereich mit OK-432
HNO, 2005Co-Authors: Marc Bloching, G. Götze, M. Passmann, K. NeumannAbstract:Background The intralesional injection of OK-432 has been proposed as an effective treatment of lymphangiomas and ranulas. The aim of this study was to review our experience with sclerotherapy of benign cervical cysts as an alternative method to surgical extirpation. Patients and methods We performed a case note review of six patients who received OK-432 injections in a concentration of 0.01 mg/ml between March 2002 and December 2003. Results Disappearance of the lesions was achieved after one to three injections in all patients. We found a complete remission in two of six patients and a marked reduction in four of six patients. There were no significant complications observed. Conclusion OK-432 is an effective alternative in the treatment of benign cervical cysts, but it is very important to exclude malignancy-associated diseases before instillation of OK-432. Long-term results will be awaited. Hintergrund Die Wirksamkeit einer intraläsionalen Sklerosierungsbehandlung des Lymphangioms und der Ranula mit OK-432 (Picibanil) wurde in mehreren klinischen Studien nachgewiesen. Das Ziel der Studie war die Überprüfung der Wirksamkeit einer Sklerosierung mit Picibanil bei gutartigen zystischen Halsraumforderungen. Patienten und Methoden Im Zeitraum zwischen März 2002 und Dezember 2003 behandelten wir 6 Patienten mit zystischen Halsraumforderungen intraläsional mit Picibanil in einer Dosierung von 0,01 mg/ml. Ergebnisse Wir verwendeten Picibanil bisher bei 6 Patienten mit gutem Erfolg. In 2 Fällen kam es klinisch und sonographisch zu einer kompletten Rückbildung der Zyste. In 4 Fällen bildete sich die Raumforderung so weit zurück, dass nur noch sonographisch ein nachweisbarer Restbefund verblieb, der in 2 Fällen komplett sklerosiert war. Sollte sich nach 4–6 Wochen kein eindeutiges Ansprechen der Zyste auf die Injektionsbehandlung zeigen, ist eine zeitnahe Exstirpation zur Gewinnung einer aussagefähigen Histologie indiziert. Es zeigten sich keine wesentlichen Komplikationen nach Picibanil-Sklerosierung. Schlussfolgerungen Die Anwendung von OK-432 (Picibanil) stellt nach unseren bisherigen Ergebnissen eine risikoarme Methode zur Sklerosierung von gutartigen zystischen Halsraumforderungen dar, die in vielen Fällen die operative Exstirpation ersetzen kann. Grundsätzlich muss jedoch vor jeder Picibanil-Behandlung das Risiko für eine maligne Erkrankung weitestgehend ausgeschlossen werden.
-
Sklerotherapie zystischer Raumforderungen im Halsbereich mit OK-432
HNO, 2005Co-Authors: Marc Bloching, G. Götze, M. Passmann, K. NeumannAbstract:Die Wirksamkeit einer intralasionalen Sklerosierungsbehandlung des Lymphangioms und der Ranula mit OK-432 (Picibanil) wurde in mehreren klinischen Studien nachgewiesen. Das Ziel der Studie war die Uberprufung der Wirksamkeit einer Sklerosierung mit Picibanil bei gutartigen zystischen Halsraumforderungen. Im Zeitraum zwischen Marz 2002 und Dezember 2003 behandelten wir 6 Patienten mit zystischen Halsraumforderungen intralasional mit Picibanil in einer Dosierung von 0,01 mg/ml. Wir verwendeten Picibanil bisher bei 6 Patienten mit gutem Erfolg. In 2 Fallen kam es klinisch und sonographisch zu einer kompletten Ruckbildung der Zyste. In 4 Fallen bildete sich die Raumforderung so weit zuruck, dass nur noch sonographisch ein nachweisbarer Restbefund verblieb, der in 2 Fallen komplett sklerosiert war. Sollte sich nach 4–6 Wochen kein eindeutiges Ansprechen der Zyste auf die Injektionsbehandlung zeigen, ist eine zeitnahe Exstirpation zur Gewinnung einer aussagefahigen Histologie indiziert. Es zeigten sich keine wesentlichen Komplikationen nach Picibanil-Sklerosierung. Die Anwendung von OK-432 (Picibanil) stellt nach unseren bisherigen Ergebnissen eine risikoarme Methode zur Sklerosierung von gutartigen zystischen Halsraumforderungen dar, die in vielen Fallen die operative Exstirpation ersetzen kann. Grundsatzlich muss jedoch vor jeder Picibanil-Behandlung das Risiko fur eine maligne Erkrankung weitestgehend ausgeschlossen werden.
Myung-whun Sung - One of the best experts on this subject based on the ideXlab platform.
-
ok 432 sclerotherapy in head and neck lymphangiomas long term follow up result
Otolaryngology-Head and Neck Surgery, 2009Co-Authors: Jae Chul Yoo, Myung-whun Sung, Youngjin Ahn, Yune Syung Lim, Hun J Hah, Tackkyun Kwon, Kwang Hyun KimAbstract:Introduction Nonsurgical treatments, such as sclerotherapy have been attempted for head and neck lymphagiomas. Of the available sclerosing agents, Picibanil has shown satisfactory short-term treatment results in many studies, but no study has presented long-term treatment results. Accordingly, in the present study, the authors retrospectively reviewed the long-term treatment results of Picibanil sclerotherapy. Materials and Methods Fifty-five lymphangioma patients who underwent Picibanil sclerotherapy were enrolled. Data about initial and long-term response, recurrence, and excision rate were collected. Results Initial response rates were 83.5 percent and long-term response rates were 76.3 percent. Conclusion Initial and the long-term response rate were equally good for lymphangioma.
-
Picibanil sclerotherapy for intractable chylous leakage after neck dissection
Korean Journal of Otorhinolaryngology-head and Neck Surgery, 2008Co-Authors: Hyun Chang, Youngjin Ahn, Myung-whun Sung, Kwang Hyun KimAbstract:Injury of the thoracic duct after radical neck dissection is a well known complication that occurs in about 2% of patients who undergo radical neck dissection. Subsequent chyle leakage can cause complications such as skin flap necrosis, orocutaneous fistula, electrolyte imbalance and protein loss. Chyle leakage is managed conservatively with total parenteral nutrition and mediumchain triglyceride diet or is treated surgically with leakage site ligation or thoracic duct ligation. Sclerotherapy can be one of the treatment options and tetracycline and povidone-iodine have been reported to be used as sclerosing agents. However, Picibanil sclerotheray for post-neck dissection chyle leakage has not been reported. This paper presents our experience in the management of a intractable chyle leakage which was irresponsive to conservative management and thoracic duct ligation, by successfully employing Picibanil. (Korean J Otorhinolaryngol-Head Neck Surg 2008;51:846-9)
-
sclerotherapy with Picibanil ok 432 for congenital lymphatic malformation in the head and neck
Laryngoscope, 2001Co-Authors: Kwang Hyun Kim, Myung-whun Sung, Dongwook Lee, Dongyoung Kim, Sangjun Lee, Chan Ho Hwang, Seokwoo ParkAbstract:Hypothesis/Objectives: Congenital lymphatic malformations of the head and neck (LMHN) present special challenges to the otolaryngologist-head and neck surgeon. Recently, a number of sclerotherapy trials have shown promising results. In this study, we present our experiences with Picibanil (OK-432) sclerotherapy for this lesion. Study Design: Retrospectively review. Methods: We retrospectively reviewed 21 patients who have undergone sclerotherapy with Picibanil for LMHN. Results: Satisfactory response with complete or nearly complete shrinkage of the lesions was observed in 15 cases after repeated sclerotherapy (average, two times). We did not observe any significant morbidity or complications in the patients treated with Picibanil. Reduction in size of the mass was achieved in weeks to months. Some of the patients who had not had any other previous treatment showed remarkable reductions in size even after the first therapy. When we used Picibanil sclerotherapy as a primary treatment for the LMHN, most of our patients showed satisfactory results regardless of the size or location of the lesions. Conclusion: Given with our experience and the reports that failure of Picibanil sclerotherapy does not hinder subsequent surgical salvage procedures, we recommend trying Picibanil sclerotherapy as a primary treatment for the LMHN and performing surgical excision as a secondary modality if the response to the sclerotherapy is not satisfactory.
Marc Bloching - One of the best experts on this subject based on the ideXlab platform.
-
Sclerotherapy of cervical cysts with Picibanil (OK-432).
European Archives of Oto-Rhino-Laryngology, 2006Co-Authors: Stephan Knipping, K. Neumann, Gerrit Goetze, Marc BlochingAbstract:The effectiveness of intralesional sclerotherapy of lymphangiomas and ranulas with OK-432 (Picibanil) has been proved in several clinical studies. The aim of our study was to review the effectiveness of sclerotherapy of benign cervical cysts with Picibanil as an alternative method to surgical excision. Between March 2002 and March 2006, a prospective observational study was carried out to assess the effects of Picibanil on cervical cysts. Between 2002 and 2006 we treated 14 patients having cervical cysts through intralesional application of Picibanil with a dose of 0.01 mg/ml. So far we used Picibanil with 13 patients achieving a high success rate. In eight cases we observed, both clinically and ultrasonographically, a nearly complete regression, and a complete regression of the cysts in three cases. In two cases the cysts atrophied. In these cases only residual findings could be observed. In one case we extirpated the remaining cyst. If there is no clear reaction of the cyst to the treatment, an excision is indicated 6 weeks after the injections to gain meaningful histological examination. No significant complication after sclerotherapy with Picibanil was observed. According to our results the application of OK-432 (Picibanil) is a safe and effective primary method for sclerotherapy of benign cervical cysts which can replace surgical extirpation in special cases. However, the risk of malign diseases has to be excluded before the commencement of the Picibanil treatment.
-
Sklerotherapie zystischer Raumforderungen im Halsbereich mit OK-432
HNO, 2005Co-Authors: Marc Bloching, G. Götze, M. Passmann, K. NeumannAbstract:Background The intralesional injection of OK-432 has been proposed as an effective treatment of lymphangiomas and ranulas. The aim of this study was to review our experience with sclerotherapy of benign cervical cysts as an alternative method to surgical extirpation. Patients and methods We performed a case note review of six patients who received OK-432 injections in a concentration of 0.01 mg/ml between March 2002 and December 2003. Results Disappearance of the lesions was achieved after one to three injections in all patients. We found a complete remission in two of six patients and a marked reduction in four of six patients. There were no significant complications observed. Conclusion OK-432 is an effective alternative in the treatment of benign cervical cysts, but it is very important to exclude malignancy-associated diseases before instillation of OK-432. Long-term results will be awaited. Hintergrund Die Wirksamkeit einer intraläsionalen Sklerosierungsbehandlung des Lymphangioms und der Ranula mit OK-432 (Picibanil) wurde in mehreren klinischen Studien nachgewiesen. Das Ziel der Studie war die Überprüfung der Wirksamkeit einer Sklerosierung mit Picibanil bei gutartigen zystischen Halsraumforderungen. Patienten und Methoden Im Zeitraum zwischen März 2002 und Dezember 2003 behandelten wir 6 Patienten mit zystischen Halsraumforderungen intraläsional mit Picibanil in einer Dosierung von 0,01 mg/ml. Ergebnisse Wir verwendeten Picibanil bisher bei 6 Patienten mit gutem Erfolg. In 2 Fällen kam es klinisch und sonographisch zu einer kompletten Rückbildung der Zyste. In 4 Fällen bildete sich die Raumforderung so weit zurück, dass nur noch sonographisch ein nachweisbarer Restbefund verblieb, der in 2 Fällen komplett sklerosiert war. Sollte sich nach 4–6 Wochen kein eindeutiges Ansprechen der Zyste auf die Injektionsbehandlung zeigen, ist eine zeitnahe Exstirpation zur Gewinnung einer aussagefähigen Histologie indiziert. Es zeigten sich keine wesentlichen Komplikationen nach Picibanil-Sklerosierung. Schlussfolgerungen Die Anwendung von OK-432 (Picibanil) stellt nach unseren bisherigen Ergebnissen eine risikoarme Methode zur Sklerosierung von gutartigen zystischen Halsraumforderungen dar, die in vielen Fällen die operative Exstirpation ersetzen kann. Grundsätzlich muss jedoch vor jeder Picibanil-Behandlung das Risiko für eine maligne Erkrankung weitestgehend ausgeschlossen werden.
-
Sklerotherapie zystischer Raumforderungen im Halsbereich mit OK-432
HNO, 2005Co-Authors: Marc Bloching, G. Götze, M. Passmann, K. NeumannAbstract:Die Wirksamkeit einer intralasionalen Sklerosierungsbehandlung des Lymphangioms und der Ranula mit OK-432 (Picibanil) wurde in mehreren klinischen Studien nachgewiesen. Das Ziel der Studie war die Uberprufung der Wirksamkeit einer Sklerosierung mit Picibanil bei gutartigen zystischen Halsraumforderungen. Im Zeitraum zwischen Marz 2002 und Dezember 2003 behandelten wir 6 Patienten mit zystischen Halsraumforderungen intralasional mit Picibanil in einer Dosierung von 0,01 mg/ml. Wir verwendeten Picibanil bisher bei 6 Patienten mit gutem Erfolg. In 2 Fallen kam es klinisch und sonographisch zu einer kompletten Ruckbildung der Zyste. In 4 Fallen bildete sich die Raumforderung so weit zuruck, dass nur noch sonographisch ein nachweisbarer Restbefund verblieb, der in 2 Fallen komplett sklerosiert war. Sollte sich nach 4–6 Wochen kein eindeutiges Ansprechen der Zyste auf die Injektionsbehandlung zeigen, ist eine zeitnahe Exstirpation zur Gewinnung einer aussagefahigen Histologie indiziert. Es zeigten sich keine wesentlichen Komplikationen nach Picibanil-Sklerosierung. Die Anwendung von OK-432 (Picibanil) stellt nach unseren bisherigen Ergebnissen eine risikoarme Methode zur Sklerosierung von gutartigen zystischen Halsraumforderungen dar, die in vielen Fallen die operative Exstirpation ersetzen kann. Grundsatzlich muss jedoch vor jeder Picibanil-Behandlung das Risiko fur eine maligne Erkrankung weitestgehend ausgeschlossen werden.
Richard J H Smith - One of the best experts on this subject based on the ideXlab platform.
-
treatment of lymphangiomas in children an update of Picibanil ok 432 sclerotherapy
Otolaryngology-Head and Neck Surgery, 1999Co-Authors: John H Greinwald, Diane K Burke, Yukato Sato, Rolland I Poust, Ken Kimura, Nancy M Bauman, Richard J H SmithAbstract:Picibanil (OK-432) is a sclerosing agent derived from a low-virulence strain of Streptococcus pyogenes that induces regression of macrocystic lymphangiomas. This report describes a prospective, nonrandomized trial to evaluate the efficacy of Picibanil in the treatment of 13 affected children ranging in age from 1 to 94 months. On average, 4.1 fluoroscopically guided intracystic injections were performed per child, with an average total dose of 0.56 mg of Picibanil. As judged by physical examination and radiographic studies, 5 children (42%) showed a complete or substantial response, and 2 children (16%) showed an intermediate response. No response was seen in 5 children (42%), 2 of whom had massive craniofacial lymphangioma. Factors that contribute to failure with Picibanil sclerotherapy are the presence of a significant micro-cystic component to the lesion, massive craniofacial involvement, and previous surgical resection. Macrocystic lymphangiomas of the infratemporal fossa or cervical area have the bes...